Lexeo Therapeutics
Scientist I/II, In Vivo Pharmacology
- Compensation
- $111.4K–$150K / yr
- Location
- New York, NY, US
- Arrangement
- On-site
- Employment type
- Full-time
- Posted
- 21 October 2026 (25 days ago)
Checked 19 days agoApplications go to the employer, never to RoleSprint
About this role
Primary Responsibilities • Design and execute in vivo studies that de-risk novel targets, using genetic knockdown/overexpression and tool molecules to test target–phenotype links
• Outsource or internally establish rodent cardiac disease models, including transgenic lines and surgical models such as TAC and MI
• Run therapeutic screening studies that rank candidates on efficacy, dose-response, durability, and identify hit molecules for advancement
• Dose by multiple routes (IV, IP, SC, IM, PO, retro-orbital) and by osmotic minipump across longitudinal studies
• Lead study takedowns: necropsy, blood and tissue collection, and processing for histology, molecular, and ex vivo endpoints, including Langendorff cardiac dissociation
• Partner with Translational Sciences to establish bioanalytical methods for biodistribution and target engagement in rodent tissues, and align on models with clinical endpoints/biomarkers
• Analyze, interpret, and present data to project teams; keep study records in the ELN in line with IACUC and animal welfare standards
• Manage study logistics, manage budgets, flag capacity or timeline risks early, and ideate novel methods for pharmacology and physiology
Required Skills and Qualifications • PhD in physiology, pharmacology, cardiovascular biology, or a related field with 0–3 years of postdoctoral or industry experience; or MS with 5+ years of industry experience
• Hands-on rodent experience: handling, multi-route dosing, blood collection, survival surgery, and necropsy
• Track record using rodent disease models for target validation or efficacy testing of molecules
• Proven understanding of power analyses, methods of randomizing animal models and appropriate uses of statistical methods
• Strong data analysis skills (e.g., GraphPad) and clear written and verbal communication
• Organized and independent; able to run several longitudinal studies at once within a collaborative team
• Ability to regularly work onsite at HQ in New York City
Preferred Skills and Qualifications • Industry experience in a small, fast-paced biotech is highly preferred
• Working knowledge of qPCR/ddPCR for vector/mRNA, ELISA/LC-MS for ASO, RNAscope/IHC for tissue localization, WB/ ELISA/MSD for protein detection
• Hands-on echocardiography in mice and rats (e.g., Vevo)
• ECG and blood pressure telemetry implantation and analysis in mice and rats (e.g., Ponemah)
• Cardiac surgical models (TAC, MI) and invasive hemodynamics (PV-loop)
• Demonstrated experience with models of neurodegenerative disease, particularly ataxia or cerebellar disorders, including execution and interpretation of rotarod, gait analysis, balance beam, grip strength, and longitudinal behavioral studies
• In vivo experience working with and advancing AAV or oligonucleotide therapeutics
• Experience selecting and evaluating CROs to perform animal studies
• AALAS certification or equivalent
Work location
- New York, NY, US
Related jobs
Ready to make a decision?
This role is either worth your time or it isn’t.
Analyze the posting against your experience, see the gaps clearly, and build the right materials only if the opportunity makes sense.
Nothing is submitted automatically. You choose what happens next.
About this listing
Published on Lever under the board identifier Lexeotx, which is the name the employer’s own job board carries. RoleSprint has not verified the company’s registered or trading name, so it is shown exactly as published rather than tidied up.
RoleSprint is not the employer and not a recruiter. Applications are made on the employer’s own site and never reach us; what RoleSprint does is help you decide whether a role is worth your time and prepare for it if it is.
Published 21 October 2026, last checked 19 days ago. A posting stops being advertised here 90 days after the employer published it, and one the employer takes down is marked closed rather than quietly removed.